Sata Masataka, Fukuda Daiju, Tanaka Kimie, Kaneda Yukari, Yashiro Hisako, Shirakawa Ibuki
Department of Cardiovascular Medicine, University of Tokyo, Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
J Cell Mol Med. 2005 Jul-Sep;9(3):557-68. doi: 10.1111/j.1582-4934.2005.tb00488.x.
The accumulation of smooth muscle cells (SMCs) plays a principal role in atherogenesis, post-angioplasty restenosis and transplantation-associated vasculopathy. Therefore, much effort has been expended in targeting the migration and proliferation of medial smooth muscle cells to prevent occlusive vascular remodeling. Recent evidence suggests that bone marrow-derived circulating precursors can also give rise to endothelial cells and smooth muscle cells that contribute to vascular repair, remodeling, and lesion formation under physiological and pathological conditions. This article overviews recent findings on circulating vascular progenitor cells and describes potential therapeutic strategies that target these cells to treat occlusive vascular diseases.
平滑肌细胞(SMC)的积聚在动脉粥样硬化、血管成形术后再狭窄以及移植相关血管病变中起主要作用。因此,人们在针对中膜平滑肌细胞的迁移和增殖以预防闭塞性血管重塑方面付出了很多努力。最近的证据表明,骨髓来源的循环前体细胞也可分化为内皮细胞和平滑肌细胞,在生理和病理条件下参与血管修复、重塑和病变形成。本文综述了循环血管祖细胞的最新研究发现,并描述了针对这些细胞治疗闭塞性血管疾病的潜在治疗策略。